CARDIOME PHARMA CORP's ticker is CRME and the CUSIP is 14159U301. A total of 30 filers reported holding CARDIOME PHARMA CORP in Q3 2015. The put-call ratio across all filers is 4.66 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $118,000 | +47.5% | 51,200 | -0.4% | 0.00% | – |
| Q4 2017 | $80,000 | -27.3% | 51,400 | 0.0% | 0.00% | – |
| Q3 2017 | $110,000 | -52.6% | 51,400 | 0.0% | 0.00% | – |
| Q2 2017 | $232,000 | +45.0% | 51,400 | -3.0% | 0.00% | – |
| Q1 2017 | $160,000 | +9.6% | 53,000 | 0.0% | 0.00% | – |
| Q4 2016 | $146,000 | -12.0% | 53,000 | 0.0% | 0.00% | – |
| Q3 2016 | $166,000 | -8.8% | 53,000 | +49.0% | 0.00% | – |
| Q2 2016 | $182,000 | +24.7% | 35,580 | 0.0% | 0.00% | – |
| Q1 2016 | $146,000 | -48.2% | 35,580 | +2.1% | 0.00% | – |
| Q4 2015 | $282,000 | +13.7% | 34,840 | +18.7% | 0.00% | – |
| Q3 2015 | $248,000 | 0.0% | 29,360 | +11.1% | 0.00% | – |
| Q2 2015 | $248,000 | +40.9% | 26,420 | +38.6% | 0.00% | – |
| Q1 2015 | $176,000 | +57.1% | 19,060 | +57.3% | 0.00% | – |
| Q4 2014 | $112,000 | +166.7% | 12,120 | +155.7% | 0.00% | – |
| Q3 2014 | $42,000 | – | 4,740 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 3,241,550 | $7,520,000 | 4.03% |
| Tamarack Advisers, LP | 1,875,000 | $4,350,000 | 2.07% |
| CLOUGH CAPITAL PARTNERS L P | 2,075,663 | $4,816,000 | 0.46% |
| Rock Springs Capital Management LP | 1,200,000 | $2,784,000 | 0.12% |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 4,192,034 | $9,726,000 | 0.08% |
| PUTNAM INVESTMENTS LLC | 3,092,133 | $7,174,000 | 0.02% |
| Renaissance Technologies | 528,913 | $1,227,000 | 0.00% |
| SCOTIA CAPITAL INC. | 19,120 | $44,000 | 0.00% |
| PNC FINANCIAL SERVICES GROUP, INC. | 51,200 | $118,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 700 | $2,000 | 0.00% |